Living with IPF: Colin’s Story
Colin was diagnosed with idiopathic pulmonary fibrosis. Watch the video to see his testimony. Learn more about IPF : https://bit.ly/1QiRmr3…
Living with IPF: Colin’s Story
IPF Patients with Chronic Cough Sought for Phase 2 Clinical Trial
Afferent Pharmaceuticals, a biotechnology company dedicated to therapies for neurogenic disorders, recently announced the beginning of a Phase 2 clinical trial to assess its candidate product AF-219 for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Neurogenic disorders are conditions associated with the central nervous…
Last Week’s Top-3 Most Read Posts On Pulmonary Fibrosis
Read the articles here: 1. Potential Therapy for Severe Lung Disease Advances at aTyr Pharma 2. New Anti-Fibrotic Drug Candidate MRG-201 Enters Phase 1 Clinical Trial 3. Genentech’s IPF Therapy Found to Improve Lung Function over Time…
Pulmonary Fibrosis Patients With PH Get Techno Boost in phaware365 App
The nonprofit phaware global association (phaware), an organization focused on raising awareness of pulmonary hypertension, has developed a new mobile app (phaware365) to help achieve its goal globally through an innovative and engaging strategy. Pulmonary hypertension (PH) is a life-threatening cardiopulmonary disorder characterized by an abnormally high blood pressure…
Genentech’s IPF Therapy Found to Improve Lung Function over Time
New data from Phase 3 clinical studies of Genentech’s Esbriet (pirfenidone), a drug developed for the treatment of pulmonary fibrosis (PF), showed the treatment’s efficacy over time. The data presentation, the “Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in…
Dr. Ferran Morell Brotad talks about Pulmonary Fibrosis
Watch the video to learn a little bit more about Pulmonary Fibrosis, causes, symptoms and signs. Learn more about PF here: https://bit.ly/1lfMsiZ…
Genentech Helps Pulmonary Fibrosis Foundation Programs
The Pulmonary Fibrosis Foundation (PFF), an organization whose goal is to raise awareness, offer disease education, advance care, and fund research in the field of pulmonary fibrosis (PF), announced in a press release that Genentech, a biotechnology company part of the Roche Group, will assume the role…
Potential IPF Disease Biomarkers Seen in Patients’ Blood
Findings by a team of researchers suggest that levels of circulating endothelial cells and fibrocytes may be used as predictive biomarkers in idiopathic pulmonary fibrosis (IPF). The team’s study, “Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments,” was published in the journal…
Esbriet’s Promise and Potential as a PF Therapy
Esbriet (pirfenidone, Genentech) is an anti-fibrotic drug developed as a therapy for pulmonary fibrosis (PF), and was the first drug to receive approval for PF treatment in the United States. New data on Esbriet was recently presented by Dr. Steven Nathan, Medical Director, Advanced Lung Disease…
Love Your Lungs – Living With Idiopathic Pulmonary Fibrosis
https://www.youtube.com/watch?v=CfmkE6zqT9A “Dolores has Idiopathic Pulmonary Fibrosis (IPF) and tells her story about living with lung disease. Dolores found help in dealing with her illness by contacting the Irish Lung Fibrosis Association (ILA).” Learn more about IPF: https://bit.ly/1XjPFMa…
